CASE REPORT
Year : 2017 | Volume
: 12 | Issue : 1 | Page : 55--56
A foreign body reaction to Surgicel® in a lymph node diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration
Diana Badenes1, Lara Pijuan2, Víctor Curull1, Albert Sánchez-Font1,
1 Department of Pulmonology, Hospital del Mar Parc de Salut Mar, UAB, CIBERES, ISCIII; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
2 IMIM (Hospital del Mar Medical Research Institute); Department of Pathology, Hospital del Mar Parc de Salut Mar, UAB, Barcelona, Spain
Correspondence Address:
Albert Sánchez-Font
Department of Pulmonology, Endoscopy Unit, Hospital del Mar-Parc de Salut Mar, Passeig Marítim 25-29, Barcelona 08003
Spain
Abstract
Surgicel ® (Ethicon, North Ryde, NSW, Australia) is an absorbable sheet of oxidized cellulose polyanhydroglucuronic acid polymer used as an hemostatic in cardiovascular and thoracic surgery. In some cases, the retained material may cause foreign body granulomatous reactions and simulate tumor recurrence, an abscess, an hematoma, or an infection. We report the case of a 55-year-old patient who was operated of a lung adenocarcinoma. In the thoracic computed tomography scan 1 year after the surgery, a right paratracheal lymph node was detected, so endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) was performed suspecting recurrence of the tumor. The cytology results of the lymph node showed a nonnecrotizing granulomatous reaction secondary to Surgicel ® , used as an hemostatic during the surgery. The objective of presenting this case is to consider foreign body reaction to Surgicel ® in the differential diagnosis of postoperative suspicion of neoplastic recurrence, and on the other hand, to note that EBUS-TBNA enables diagnosis.
How to cite this article:
Badenes D, Pijuan L, Curull V, Sánchez-Font A. A foreign body reaction to Surgicel® in a lymph node diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration.Ann Thorac Med 2017;12:55-56
|
How to cite this URL:
Badenes D, Pijuan L, Curull V, Sánchez-Font A. A foreign body reaction to Surgicel® in a lymph node diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration. Ann Thorac Med [serial online] 2017 [cited 2023 Mar 25 ];12:55-56
Available from: https://www.thoracicmedicine.org/text.asp?2017/12/1/55/197780 |
Full Text
Surgicel ® (Ethicon, North Ryde, NSW, Australia) is an absorbable oxidized cellulose mesh of a vegetal polyanhydroglucuronic acid polymer used in surgery as an hemostatic agent to control small bleeding, to optimize ligatures coagulation, or when electrocoagulation is not enough. [1] It is mainly used in cardiovascular surgery but also in other types of interventions. The material is deposited on the surgical bed and is usually reabsorbed during the following 7-14 days. In recent years, some complications have been described secondary to compression of surrounding anatomic structures causing the formation of granulation tissue as a foreign body reaction. [2] We describe the first case of a surgical patient with a history of pulmonary neoplasia in whom a paratracheal lymph node suspicious of tumor recurrence was detected 1 year after the surgery being diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) of foreign body reaction to Surgicel ® .
Case Report
We report the case of a 55-year-old patient, active smoker without occupational exposure who, after the discovery of a pulmonary nodule on thoracic computed tomography (CT), underwent a right upper lobectomy with lymphadenectomy that was diagnostic of pulmonary adenocarcinoma (pT1b pN0). All the lymph nodes sampled in the surgery (10R, 11R, 7, 4R, and 9R) presented sinus histiocytosis and anthracosis and were negative for metastasis. Lymph node from region 4R had fragments of bronchial cartilage introduced by EBUS-TBNA performed previously [Figure 1]a. One year later, during outpatient thoracic surgery monitoring, thoracic CT evidenced a low right paratracheal lymph node [Figure 1]b. With the suspicion of pulmonary neoplasm recurrence, EBUS-TBNA was performed [Figure 2]a]. The lymphadenopathy cytology showed a nonnecrotizing granulomatous reaction secondary to amorphous fragments of an acellular material that were birefringent under polarized light, compatible with Surgicel ® [Figure 2]b. The culture and polymerase chain reaction testing for Mycobacterium tuberculosis were negative. At 6 months of follow-up, no significant changes in the lymph node were observed.{Figure 1}{Figure 2}
Discussion
Surgicel ® , an absorbable mesh of polyanhydroglucuronic acid-oxidized cellulose polymer, is used in surgery as an hemostatic agent to control small bleeding, to optimize ligatures coagulation, and when electrocoagulation is not enough. [1] Surgicel ® acts as an anchor for platelets to initiate adhesion, aggregation, and coagulation. [3] Absorption begins at 24 h and depends on the amount of material used. Surgicel ® 's fibrous residue is phagocytized by macrophages 48 h after implantation, although a period of 4-8 weeks is required for it to be completely absorbed. Since it began to be used, cases that simulate tumor recurrence have been described in neurosurgery, gastrointestinal, and cardiac surgery, forcing additional examinations to determine an etiology of foreign body granulomatous reactions. [1],[2],[3],[4] To date, however, there have been no reported cases of suspected recurrence of pulmonary neoplasm.
The dissolution of Surgicel ® depends on the amount used and where along with environmental factors. Only the minimum amount necessary should be used; indeed, most complications reported in the literature are related to an excess of the material. [1] Surgicel ® has an uronic acid component that can increase inflammation of the surrounding tissue and delay healing of the injury. [5] Complicated degradation reactions due to tissue damage can sometimes occur such as provisional matrix formation, acute or chronic inflammation, the appearance of granulation tissue, and creation of foreign body reactions leading to the formation of a fibrous capsule. [3] It is estimated that these reactions occur in about 3% of cases. [5] With current imaging technology, it is not possible to differentiate the accumulation of Surgicel ® from possible tumor recurrence, hematoma, or abscess. In our case, the appearance of a low right paratracheal lymph node led us to suspect a recurrence of lung adenocarcinoma. We carried out EBUS-TBNA to study the lymph node.
Conclusion
The objective of this case report is to present Surgicel ® , a safe local hemostatic agent used in thoracic surgery, which reduces complications after surgery, and therefore health care costs, [5] which in a small percentage of cases may lead to complications or the appearance of lesions that can simulate abscesses or, as in the present case, nodal tumor recurrence. In this sense, granulomatous reaction to this material should be considered in the differential diagnosis of suspected lung tumor recurrence in surgically treated patients. Finally, EBUS-TBNA was a useful diagnostic approach.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
References
| 1 | Patanè F, Zingarelli E, Verzini A, di Summa M. Complication due to excessive use of surgicel. Eur J Cardiothorac Surg 2001;20:1034. |
| 2 | Eto K, Matsumoto M, Kubo Y, Kemmochi R. Superior vena cava syndrome caused by a swollen absorbable haemostat after repair of ischaemic mitral regurgitation. J Cardiothorac Surg 2014;9:1. |
| 3 | Pierce A, Wilson D, Wiebkin O. Surgicel: Macrophage processing of the fibrous component. Int J Oral Maxillofac Surg 1987;16:338-45. |
| 4 | Ibrahim MF, Aps C, Young CP. A foreign body reaction to Surgicel mimicking an abscess following cardiac surgery. Eur J Cardiothorac Surg 2002;22:489-90. |
| 5 | Tomizawa Y. Clinical benefits and risk analysis of topical hemostats: A review. J Artif Organs 2005;8:137-42. |
|
